Video Experimental Relacionado
Updated: Feb 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Inhibición del Factor XI en la fibrilación auricular: ¿dónde estamos?
Simona Giubilato1, Davide Capodanno2
1U.O.C. di UTIC con Cardiologia ed Emodinamica, AOE Cannizzaro, Catania.
Los inhibidores del Factor XI (FXI) prometen prevenir coágulos sanguíneos con menor riesgo de hemorragia. Sin embargo, los ensayos clínicos revelan resultados mixtos sobre su eficacia, lo que requiere una mayor investigación para el tratamiento de la fibrilación auricular (FA).
Videos de Conceptos Relacionados
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Clot Retraction and Fibrinolysis
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

